← Back to patent-cliff list
ITU-512
Tier C — Watch / tradeITU-512
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：WIZ, CRBN
Indications (approved)：Sickle cell disease
Regional status
US
Phase II
2024-08-15
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ITU-512?
Approved indications include: Sickle cell disease.
When does the ITU-512 patent expire?
No public expiry year is available for ITU-512 yet; this page updates once verified.
How do I get a quote for ITU-512 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01